Oversea Chinese Banking Corp LTD Bei Gene, Ltd. Transaction History

Oversea Chinese Banking Corp LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$129.52 - $174.32 $268,365 - $361,191	-2,072 Reduced 42.5%	2,803 $399,000
Q1 2024 May 13, 2024	SELL	$141.8 - $181.47 $359,746 - $460,389	-2,537 Reduced 34.23%	4,875 $762,000
Q4 2023 May 21, 2024	BUY	$158.67 - $201.58 $402,545 - $511,408	2,537 Added 52.04%	7,412 $1.34 Million
Q4 2023 Jan 31, 2024	SELL	$158.67 - $201.58 $352,564 - $447,910	-2,222 Reduced 23.06%	7,412 $1.34 Million
Q3 2023 Apr 29, 2024	BUY	$179.87 - $225.13 $399,671 - $500,238	2,222 Added 29.98%	9,634 $1.73 Million
Q3 2023 Nov 03, 2023	BUY	$179.87 - $225.13 $801,680 - $1 Million	4,457 Added 86.09%	9,634 $1.73 Million
Q2 2023 Aug 08, 2023	BUY	$178.3 - $266.78 $215,029 - $321,736	1,206 Added 30.37%	5,177 $923,000
Q1 2023 Sep 15, 2023	BUY	$215.53 - $274.5 $855,869 - $1.09 Million	3,971 Added 314.66%	5,233 $1.13 Million
Q1 2023 May 08, 2023	BUY	$215.53 - $274.5 $583,870 - $743,620	2,709 Added 214.66%	3,971 $855,000
Q4 2022 Sep 15, 2023	SELL	$125.51 - $229.3 $491,371 - $897,709	-3,915 Reduced 75.62%	1,262 $277,000
Q4 2022 Feb 13, 2023	BUY	$125.51 - $229.3 $158,393 - $289,376	1,262 New	1,262 $0

249

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Oversea Chinese Banking Corp LTD, based on Form 13F filings with the SEC.

Stay updated on Oversea Chinese Banking Corp LTD with notifications on news.